10338 studies found for:    NCI
Show Display Options
RSS Create an RSS feed from your search for:
NCI
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Duct Cell Adenocarcinoma of the Pancreas;   Stage IV Pancreatic Cancer
Interventions: Drug: bortezomib;   Drug: gemcitabine hydrochloride
2 Completed Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
Condition: Head and Neck Cancer
Interventions: Biological: filgrastim;   Drug: fluorouracil;   Drug: hydroxyurea;   Drug: paclitaxel;   Procedure: conventional surgery;   Radiation: radiation therapy
3 Completed Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer;   Thromboembolism
Interventions: Drug: acetylsalicylic acid;   Drug: alvocidib;   Drug: clopidogrel bisulfate
4 Recruiting MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Somatostatinoma;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: TORC1/2 inhibitor MLN0128;   Biological: ziv-aflibercept;   Other: laboratory biomarker analysis
5 Completed
Has Results
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: tanespimycin
6 Completed Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
Conditions: Recurrent Melanoma;   Stage III Melanoma
Interventions: Drug: isolated limb perfusion;   Drug: melphalan;   Biological: recombinant tumor necrosis factor family protein;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Active, not recruiting Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: belinostat;   Drug: isotretinoin;   Other: pharmacological study
8 Active, not recruiting Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: selumetinib;   Other: laboratory biomarker analysis
9 Completed
Has Results
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Gastrointestinal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: erlotinib hydrochloride;   Biological: bevacizumab
10 Completed Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Intervention: Biological: recombinant interleukin-12
11 Completed
Has Results
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Intervention: Drug: sorafenib tosylate
12 Completed Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Condition: Head and Neck Cancer
Intervention: Drug: gefitinib
13 Completed Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
Conditions: Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: filgrastim;   Drug: becatecarin;   Drug: cisplatin
14 Completed A Phase II Study of UCN-01 in Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: 7-hydroxystaurosporine;   Other: laboratory biomarker analysis;   Other: pharmacological study
15 Unknown  Lymphocyte Therapy in Treating Patients With Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: aldesleukin;   Biological: muromonab-CD3;   Biological: therapeutic autologous lymphocytes;   Procedure: adjuvant therapy
16 Completed Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis
17 Completed Resveratrol in Postmenopausal Women With High Body Mass Index
Condition: Healthy, no Evidence of Disease
Interventions: Drug: resveratrol;   Other: laboratory biomarker analysis
18 Completed Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Conditions: Stage III Gastric Cancer;   Stage IV Gastric Cancer
Interventions: Drug: bryostatin 1;   Drug: cisplatin;   Other: laboratory biomarker analysis
19 Completed Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
20 Recruiting Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Biological: bevacizumab;   Biological: anti-endoglin monoclonal antibody TRC105;   Other: laboratory biomarker analysis;   Other: pharmacological study

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years